AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.

Summary

The legislation amends Delaware’s step‑therapy exception process to allow health insurers, plans, and utilization‑review entities to require patients to try an AB‑rated generic, an interchangeable biological product, or a biosimilar before covering the brand‑name version. It affects patients who need specialty drugs, as well as insurers and review entities that manage drug coverage. The change updates the law to reflect newer treatment options that were not available when the original statute was written.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share